Alongside the International Society of Cell & Gene Therapy (ISCT), it is my privilege
as Senior Editor of Cytotherapy to introduce to you this latest addition to the “Talking with Giants” series – a
special “Talking with Giants” Trilogy. Celebrating the highly successful development of the first chimeric antigen receptor
T cell (CAR-T) therapy, this novel immunotherapy, pioneered by the University of Pennsylvania,
has shown remarkable clinical results, pushing the rapid approval of CAR-T therapies
for treating pediatric and adult patients suffering from leukemia and lymphoma. This
advancement has pushed, in turn, the development of personalized cellular therapies
for treating both bloodborne and potentially tumorous cancers, offering new hope to
many cancer patients.
To read this article in full you will need to make a payment
© 2019 Published by Elsevier Inc. on behalf of International Society for Cell and Gene Therapy.